Description

AbbVie, Inc.: An Analysis Of Its Immunology Market Expansion, Oncology Pipeline & ADC Strategy!

AbbVie Inc. concluded 2024 with robust performance metrics, highlighted by a notable return to growth, despite significant challenges such as the $5 billion U.S. Humira sales erosion due to biosimilar competition. The company reported a total revenue of $56.3 billion, surpassing its initial guidance by over $2 billion, with adjusted earnings per share recorded at $10.12, which is $0.49 above their previously forecasted midpoint. On a segmented basis, AbbVie’s “ex-Humira” platform, consisting primarily of Skyrizi and Rinvoq, demonstrated substantial growth. This segment, excluding Humira, achieved over 18% sales growth, with revenue growth further accelerating to 22% in the last quarter. Combined sales of Skyrizi and Rinvoq alone are predicted to potentially achieve nearly $24 billion in 2025, significantly contributing to AbbVie’s anticipated mid-single-digit revenue growth.

Our Report Structure:

⦁ Company Overview
⦁ Investment Thesis
⦁ Key Drivers
⦁ Historical Quarterly Statement Analysis – Income Statement & Cash Flows
⦁ Historical Quarterly Balance Sheet Analysis
⦁ Historical Annual Financial Statement Analysis
⦁ Analysis Of Key Financial Ratios
⦁ Financial Forecasts For 3 Years
⦁ Forecasting The Capital Structure & Net Debt
⦁ Discounted Cash Flow Valuation
⦁ Trading Multiples
⦁ Key Risks
⦁ Disclosures

Want unlimited access to our reports? Purchase our $99 annual subscription!